

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** ██████████  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**JAK2 Exon 12 Mutation Analysis by PCR**

ARUP test code 2002357

JAK2 Exon 12 Mutation Analysis by PCR

Not Detected

There is no evidence of a JAK2 Exon 12 mutation. This result does not entirely exclude the possibility of a JAK2 Exon 12 mutation below the test limit of detection or one which is not detectable by the assay specific design.

This result has been reviewed and approved by ██████████  
██████████

INTERPRETIVE INFORMATION: JAK2 Exon 12 Mutation Analysis by PCR

DNA from whole blood or bone marrow is isolated and subjected to PCR amplification in the presence of a short blocking oligonucleotide homologous to exon 12 (codons 537-544) of the wild-type JAK2 gene. The oligonucleotide is designed to specifically suppress PCR amplification of wild-type JAK2 exon 12 sequence. In contrast, JAK2 exon 12 mutations located between codons 537-544 disrupt proper binding of the blocking oligonucleotide during PCR amplification resulting in a product of approximately 225 base-pairs. Each assay includes control DNA from mutation positive and wild-type negative samples all samples are tested in paired reactions with and without blocking oligonucleotide. A PCR product formed in the presence of blocking oligonucleotide indicates the presence of a mutation.

Results of this test must always be interpreted in the context of clinical and other relevant laboratory data such as erythropoietin level, exclusion of other causes of elevated hemoglobin, and should not be used alone for a diagnosis of polycythemia vera which is a form of malignancy i.e. myeloproliferative disorder.

This test is expected to detect 1 out of 1000 normal cells harboring a JAK2 exon 12 mutation.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
JAK2 Exon 12 Mutation Analysis by PCR	22-236-100081	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 22-236-100081  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 8/30/2022 4:20:55 PM  
4848